News

Explore the latest innovations in the pharmaceutical industry with FP Clinical Pharma. From pharmacokinetic studies to phase I, discover top news that drives progress and excellence in clinical services.

Wednesday, January 3, 2024

We congratulate Laboratorio BETA for the declaration of #BIOEQUIVALENCE of the product DROPICINE®/RISPERIDONE, 1mg coated tablets.

By ANMAT regulation DI-2023-5343-APN-ANMAT#MS of July 18, 2023, the results of the Bioequivalence Study designed, carried out and analyzed by FP CLINICAL PHARMA were accepted. This allowed us to declare the Bioequivalence of the DROPICINE® product? vs. RISPERDAL® from JanssenCilag Farmacéutica S.A. One more step towards better access to Medicines with Proven Quality for the Health of Argentines ANMAT Salud.

Wednesday, January 3, 2024

We are pleased to inform you that by Provision DI-2023-6029-APN-ANMAT#MS of August 7, 2023

The National Administration of Drugs, Food and Medical Technology has renewed the Authorization of FP Clinical Pharma S.R.L. to carry out PHASE IV CLINICAL PHARMACOLOGY STUDIES OF BIOEQUIVALENCE IN ADULT POPULATION.